US signs agreement to pay Moderna $1.5 billion for 100 million doses of vaccine

The US government wants first access to the vaccine for its citizens. The payment includes delivery of 100 million doses and incentive payments for timely delivery of the product.



Moderna, Inc., a biotechnology company that was the first one to use messenger RNA (mRNA) to create a new generation of transformative medicines for patients, has signed an agreement worth $1.525 billion with the U.S. government to supply 100 million doses of mRNA-1273 vaccine.

The US government wants first access to the vaccine for its citizens. The more than billion dollars is for the manufacturing and delivery of 100 million doses, including incentive payments for timely delivery of the product.

The US government has already awarded $955 million through the Biomedical Advanced Research and Development Authority (BARDA) for the development of mRNA-1273 to the company and the latest announcement brings the government’s commitments for early access to mRNA-1273 to up to $2.48 billion.

Moderna Therapeutics Coronavirus COVID vaccine

These payments are being given under the Operation Warp Speed. The government will also have the option to purchase up to an additional 400 million doses of mRNA-1273 from Moderna.

These vaccines will be delivered to the US citizens free of cost, but healthcare professionals could charge for the cost of administering the vaccine. The United States has entered into similar deals with other companies too. It has advanced purchase agreements with Johnson & Johnson, AstraZeneca Plc, Pfizer Inc and BioNTech SE, and Sanofi SA and GlaxoSmithKline Plc for their respective vaccine candidates. The agreements lock in more than 500 million doses of COVID-19 vaccine for the country. Some others like Japan, the United Kingdom, and Germany have entered into similar agreements with various companies who are in the third phase of clinical trials.

All this is incumbent on the vaccines getting health regulatory approvals from respective bodies.

Moderna’s price per dose comes to around $30.50 per person for a two-dose regimen. With the exception of its (US) deal with AstraZeneca, all the deals price COVID-19 vaccines between $20 to $42 for a two-dose course of treatment.

“We appreciate the confidence of the U.S. government in our mRNA vaccine platform and the continued support,” said Stéphane Bancel, Moderna’s Chief Executive Officer. “We are advancing the clinical development of mRNA-1273 with the ongoing Phase 3 study being conducted in collaboration with NIAID and BARDA. In parallel, we are scaling up our manufacturing capability with our strategic partners, Lonza, Catalent and Rovi, to address this global health emergency with a safe and effective vaccine.”

“For Operation Warp Speed, we are assembling a broad portfolio of vaccines to increase the odds that we will have at least one safe, effective vaccine as soon as the end of this year,” said HHS Secretary Alex Azar. “With this latest investment, we will have supported the vaccine candidate developed by Moderna in partnership with the NIH all the way from early development through clinical trials and now manufacturing, with the potential to bring millions of safe and effective doses to the American people.”

Moderna’s deal with the US only pays out in full if the drugmaker hits certain unspecific timing benchmarks for vaccine delivery.

Moderna has been involved in the development of the proprietary platform of the new class of mRNA-based vaccines since the last nine years. This investment in research has resulted in Moderna being able to create, manufacture expeditiously, and clinically develop mRNA-1273 to address the current COVID-19 pandemic potentially.

Avatar
Anna Domanska
Anna Domanska is an Industry Leaders Magazine author possessing wide-range of knowledge for Business News. She is an avid reader and writer of Business and CEO Magazines and a rigorous follower of Business Leaders.

Recent Posts

Aon – Willis asset disposal aims to ease approval of $30 billion merger

Aon – Willis asset disposal aims to ease approval of $30 billion merger

Aon Plc and Willis Towers Watson have agreed to sell $3.6 billion worth of assets to rival Arthur J. Gallagher & Co. in a bid to appease European competition regulators over th
19 hours ago
Roblox declares Q1, reports $387 million revenue as bookings increase

Roblox declares Q1, reports $387 million revenue as bookings increase

Roblox, the hugely popular online gaming platform, reported its first-quarter earnings after becoming a listed company. Its revenue more than doubled as the videogame company benef
2 days ago
Weak US job report results in volatile market

Weak US job report results in volatile market

A weak job report resulted in a record close on Friday for the US stocks. The US labor department’s monthly non-farm payrolls report revealed employers hired 266,000 new workers
3 days ago
Star and Blackstone launch bids to buyout Australia’s Crown Resorts

Star and Blackstone launch bids to buyout Australia’s Crown Resorts

A bidding war has broken out between Australian casino company Star Entertainment Group and US private equity investor Blackstone Group over Crown Resorts, Australia’s bigges
3 days ago
5 Most Expensive Divorce Settlements in History

5 Most Expensive Divorce Settlements in History

Almost half of the marriages end in divorce is an oft-quoted adage, but surprisingly, this is not true in today’s world. The reasons are varied, gender equality, the higher p
4 days ago
JPMorgan Chase appoints two new CIOS in bid to make its C-suite more diverse

JPMorgan Chase appoints two new CIOS in bid to make its C-suite more diverse

JPMorgan Chase, the largest U.S. bank by assets, has appointed two new executives to head its information units in a bid to make its workforce more inclusive and increase racial an
4 days ago